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Ab s t r a c t
Since the earliest descriptions of Alzheimer’s disease (AD), many theories have been advanced as to its cause. 
These include: (1) exacerbation of aging, (2) degeneration of anatomical pathways, including the cholinergic and 
cortico-cortical pathways, (3) an environmental factor such as exposure to aluminium, head injury, or malnutri-
tion, (4) genetic factors including mutations of amyloid precursor protein (APP) and presenilin (PSEN) genes and 
allelic variation in apolipoprotein E (Apo E), (5) mitochondrial dysfunction, (6) a compromised blood brain barrier, 
(7) immune system dysfunction, and (8) infectious agents. This review discusses the evidence for and against each 
of these theories and concludes that AD is a multifactorial disorder in which genetic and environmental risk factors 
interact to increase the rate of normal aging (‘allostatic load’). The consequent degeneration of neurons and blood 
vessels results in the formation of abnormally aggregated ‘reactive’ proteins such as b-amyloid (Ab) and tau. Gene 
mutations influence the outcome of age-related neuronal degeneration to cause early onset familial AD (EO-FAD). 
Where gene mutations are absent and a combination of risk factors present, Ab and tau only slowly accumulate not 
overwhelming cellular protection systems until later in life causing late-onset sporadic AD (LO-SAD). Ab and tau 
spread through the brain via cell to cell transfer along anatomical pathways, variation in the pathways of spread 
leading to the disease heterogeneity characteristic of AD. 
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Introduction
Ever since the first description of pre-senile de-
mentia by Alois Alzheimer in 1907 [5], the presence 
of cognitive impairment together with the forma-
tion of senile plaques (SP) and neurofibrillary tan-
gles (NFT) have been regarded as the defining clini-
co-pathological features of Alzheimer’s disease (AD) 
[13,103,126]. The term AD was first used in 1910 by 
Kraepelin based on the clinical and pathological 
description of Alzheimer’s original cases. Of the two 
cases described by Alzheimer, however, both had 
numerous SP, but only one had significant numbers 
of NFT [76], thus identifying the pathological hetero-
geneity characteristic of AD [4], and creating difficul-
ties in establishing a single theory as to its cause.
Many theories as to the cause of AD have conse-
quently been proposed. It is not the intention to dis-
cuss every theory but to concentrate on those most 
likely to be involved. Hence, the theories are dis-
cussed in eight categories: (1) acceleration of aging, 
(2) degeneration of anatomical pathways, including 
the cholinergic and cortico-cortical pathways, (3) en-
vironmental factors such as exposure to aluminium, 
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head injury, and malnutrition, (4) genetic factors 
including mutations of amyloid precursor protein 
(APP) and presenilin (PSEN) genes, and allelic vari-
ation in apolipoprotein E (Apo E), (5) a metabolic 
disorder resulting from mitochondrial dysfunction, 
(6) vascular factors such as a compromised blood 
brain barrier, (7) immune system dysfunction, and 
(8) infectious agents. This review discusses the evi-
dence for and against each of these hypotheses 
and develops a general theory as to the cause of AD. 
The implications of this theory are considered with 
reference to future research and treatment of AD.
Theories based on aging
That AD may be an accelerated form of natural 
aging is based on the observation that the many 
pathological changes in AD are similar to those 
present in normal aging apart from their severity 
[156]. Hence, in cognitively normal brain, there is an 
age-related reduction in brain volume and weight, 
enlargement of ventricles, and loss of synapses and 
dendrites in selected areas [94]. Accompanying these 
changes are the characteristic pathological features 
of AD, including SP and NFT [6]. Hence, in 60 normal 
elderly cases [117], 32/60 had no SP, although 30/60 
were younger than 65 years, 13/60 had SP in the 
hippocampus, mainly in sector CA1 and the subicu-
lum, and 12/60 had SP in temporal cortex comprising 
mainly the ‘primitive/mature’ and ‘burnt-out’ types 
of plaque. It was concluded that it was not possible 
to distinguish early-stage AD from normal aging at 
post-mortem [117]. Similarly, SP have been observed 
in 60% of normal elderly cases, albeit at lower density 
than in AD [37]. Moreover, Arrigada et al. [29] reported 
SP in most normal individuals greater than 55 years 
of age and concluded that there could be a ‘continu-
um’ of pathological change from elderly non-dement-
ed brains, early stage AD, to advanced AD [16]. 
The density of neuritic plaques (NP), which in- 
corporate dystrophic neurites (DN), and SP with 
a distinct ‘core’ (‘classic’ plaques), may not be signi-
ficantly different in AD and aging [36]. A greater vas-
cular involvement in the formation of SP has been 
observed in aging than in AD [36]. Hence, SP have 
been observed in the frontal and temporal cortex in 
15/20 patients with critical stenosis, most often in 
the depths of the gyri [180]. Alterations in cerebral 
perfusion may therefore play a role in SP formation 
and SP may not always be causally related to demen-
tia. A further study of non-demented patients with 
critical coronary artery disease suggested that some 
patients had similar densities of SP to AD, numbers 
of SP being directly proportional to the duration of 
arterial disease [181]. In addition, there may a close 
link between ischaemic brain episodes and sporadic 
cases of AD (SAD) suggesting that neovascular fac-
tors could aggravate the progression of the disease 
[150,151].
The most important molecular constituent of the 
SP is b-amyloid (Ab) [72], an approximately 4 kDa pep-
tide arising by constitutive cleavage of a trans-mem-
brane amyloid precursor protein (APP) [79]. Three 
subtypes of Ab deposit are commonly observed 
in AD, viz., diffuse, primitive, and classic deposits 
[11,55]. Studies of Ab deposition have also demon-
strated a clear overlap between AD and normal 
aging. Hence, Ab deposits were present in non-de-
mented individuals greater than 60 years but were 
rare before this age [118]. After 60 years of age, Ab 
deposits were present in a variety of diseases as 
a result of aging, especially in the temporal cortex, 
thus blurring the distinction between AD and relat-
ed disorders [118]. In 14 non-demented elderly cas-
es, Ab deposits were present in the temporal lobe 
in 8/14, but only in cortical gyri, the CA sectors of 
the hippocampus and dentate gyrus being spared 
[9]. Moreover, there was a considerable variation in 
the density of deposits in control cases and a signifi-
cant overlap with AD. The pattern of clustering of Ab 
deposits was also similar in control and AD cases, i.e., 
in cortical gyri, deposits were aggregated into clus-
ters regularly distributed parallel to the pia mater, 
suggesting a similar pathogenesis [9]. In a further 
study of centenarians [56], Ab deposits were record-
ed in the parahippocampal gyrus (PHG) of patients, 
whether demented or not, but the hippocampus was 
unaffected, suggesting a little relationship between 
lesion density and severity of mental deficits. 
Whether NFT occur as a result of normal aging 
is more controversial. The most important constitu-
ent of the paired helical filaments (PHF) and straight 
filaments which comprise cellular NFT in AD is the 
microtubule-associated protein (MAP) tau. Some stu-
dies suggest that the majority of cognitively normal 
individuals have minimal tau-immunoreactive NFT 
[105] and also less astrocytosis and microglial reac-
tion [51]. By contrast, Bouras et al. [40] found that 
all non-demented cases had NFT in lamina II of the 
entorhinal cortex (EC) and in sector CA1 of the hip-
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pocampus. Moreover, in non-demented individuals, 
NFT were more numerous in the medial temporal 
lobe and in cortical association areas when a mem-
ory deficit was present suggesting NFT could be the 
pathological substrate for memory loss in non-de-
mented as well as demented cases [82]. In the me- 
dial temporal lobe, the perforant path appears to be 
sensitive to tau-immunoreactive pathology in AD 
and these changes are distinct from those seen in 
normal aging even in the oldest individuals [67]. 
Two further aging processes may be involved in 
AD. First, an age-related breakdown of myelin [33], 
although other studies suggest that myelin loss 
occurs late in AD and is secondary to neuronal 
degeneration [43]. Second, the loss of cells in the 
locus caeruleus (LC), which provides noradrenaline 
to the cortex via terminal varicosities, and stimu-
lates microglia to suppress production of Ab [87]. 
Tau-immunoreactive NFT appear early in the LC in 
aging, mild cognitive impairment (MCI), and in AD 
apparently forming a continuum [80]. Loss of cells in 
the LC may therefore induce an age-related impair-
ment of the blood brain barrier, thus implicating vas-
cular factors in AD. 
These studies suggest that the differences bet-
ween AD and the normal elderly are largely quan-
titative rather than qualitative and there may be 
a ‘continuum’ of pathological change connecting 
these cases [17]. Nevertheless, the distribution of 
the pathology may differ in AD and control brain, 
being more localised to areas of the temporal lobe 
in aging and with a more extensive spread into 
the hippocampus and cortical association areas in 
AD [53,129,139]. An important question, therefore, 
is whether AD is an exacerbation of normal aging 
resulting from enhanced spread of the pathology 
along anatomical pathways.
Theories based on the degeneration  
of anatomical pathways
Cholinergic hypothesis
A specific degeneration of the cholinergic neu-
rotransmitter system was one of the earliest theo-
ries as to the cause of AD [148]. Several studies prior 
to 1980 showed significant losses of acetylcholine in 
the AD brain [41]. Subsequent studies also showed 
reductions of choline acetyltransferase (CAT), val-
ues in the cerebral cortex being 30-50% of those of 
controls [175], and in levels of acetylcholinesterase 
(ACHE) especially late in the disease [148]. In the 
cerebral cortex, there were correlations between the 
density of SP and levels of CAT, and in the hippocam-
pus between the density of NFT and CAT [147,148]. 
Moreover, loss of neurons was reported in the nucle-
us basalis of Meynert (nBM), a site of diffuse cho-
linergic projection to the cortex [202], and it was 
suggested that cortical SP may develop on the axon 
terminals of nBM cells [194]. Hence, AD was consid-
ered as the ‘cholinergic’ analogue of Parkinson’s dis-
ease (PD); as in the latter, there was degeneration 
of dopamine neurons originating in the substantia 
nigra, together with their cortical projections. 
Rosser and Mountjoy [163], however, cautioned 
against extrapolating data from neurotransmitter 
system studies obtained post mortem as signifi-
cant changes often occur at the extremes of life. In 
addition, it became clear that several neurotrans-
mitter-specific neurons contribute neurites to SP 
[186] and that multiple neurotransmitter deficits 
were common in AD [46]. Hence, Bowen [42] found 
increased 5-hydroxytryptamine (5-HT) turnover in AD 
and suggested that this was due to a selective loss 
of cortical 5-HT neurons and the subsequent dener-
vation of ascending projections. Hence, although 
degeneration of the cholinergic system undoubtedly 
occurs in AD, it is only a part of a more widespread 
neuronal degeneration affecting many anatomical 
pathways.
Cortico-cortical pathways
Several lines of evidence suggest degeneration 
of anatomical pathways connecting different parts 
of the cerebral cortex occurs in AD [53,139]. A major 
feature of the anatomical structure of the cerebral 
cortex is the replicated local neural circuit represent-
ed by ‘columns’ or ‘modules’ [130]. The diameter of 
individual cortical modules varies between 500 mm 
and 1000 mm, depending on the region, and there 
are specific connections between ordered sets of col-
umns [90,130]. First, there is a reciprocal projection 
between a specific cortical area and a dorsal tha-
lamic nucleus. Second, there are inputs to the cortex 
from generalised regulatory systems, e.g., from the 
basal forebrain, such as the nBM, and monoamin-
ergic nuclei of the brain stem such as the LC. Con-
sequently, the cortex is interlaced by clusters of fine 
noradrenergic fibres which repeat at 30-40 mm inter-
vals. Third, homologous neocortical areas, with the 
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exception of the striate cortex and primary somato-
sensory cortex, are reciprocally connected in both 
hemispheres via commissures, both the commis-
sural and ipsilateral association fibres terminating 
in vertically oriented columns 200-500 mm in width, 
alternating in a regular sequence with zones of com-
parable width free of such connections. Fourth, with-
in a hemisphere, different regions are connected by 
fibres of the short and long cortico-cortical projec-
tions [53,90]. The cells of origin of these projections 
are also clustered and occur in bands approximately 
500-1000 mm in width [90]. 
A number of studies suggest that AD is linked 
to degeneration of these cortical pathways. First, 
Scheff and Price [168] measured loss of synapto-
physin reactivity in the cortex in AD and related it 
to synapse loss in the temporal lobe, while Waka-
bayashi et al. [198] found a decrease in the synaptic 
marker SP6 in all regions of the AD brain. Second, 
Pearson et al. [139] studied the distribution of NFT in 
AD and observed they were located in the cell bod-
ies that give rise to the cortico-cortical pathways, SP 
developing at their terminals and collateral branch-
es. It was suggested that the disease could spread 
via these pathways in the orthograde and/or ret-
rograde direction. This pattern of spread was also 
observed by Hiorns et al. [90] who concluded that in 
AD, severely affected regions were interconnected by 
cortico-cortical pathways. The most explicit descrip-
tion of this hypothesis, however, is by De Lacoste 
and White [53] in which the authors describe AD as 
a ‘disconnection syndrome’, characterised by dis-
ruption of all afferent/efferent connections between 
the hippocampus, cortex, and the rest of the brain. 
Hence, if cortico-cortical projections are selectively 
vulnerable, the pathology may spread in a stepwise 
fashion via these connections, SP arising from the 
distal axonal projections of degenerating NFT-bear-
ing neurons [53,139]. In support of this hypothesis, 
Roberts et al. [160] postulated that regions of the 
medial temporal lobe are affected first, especially 
laminae II pre-a neurons of the EC, followed by asso-
ciation areas, and then the primary sensory areas. 
EC neurons exhibit high levels of APP, which is con-
verted into Ab at the synaptic terminal resulting in 
loss of synaptic connectivity [160]. Several studies 
also suggest that NFT in AD exhibit a spatial pattern 
consistent with their development in relation to the 
cortico-cortical pathways [25]. Hoesen and Solodkin 
[91], for example, showed that NFT selectively dam-
age strips of the cortex and hippocampus, columns 
of NFT exhibiting a regular periodicity repeating 
every 80-120 mm and representing 4-5 cell diame-
ters, and with a spacing of 300 mm. With a greater 
duration of disease, NFT gradually filled up these 
columns giving rise to clusters of NFT of increasing 
size, a result also reported by Armstrong [8]. 
Cell to cell transfer of pathogenic 
proteins
One of the first studies to suggest that the degen-
eration in AD could spread across normal synaptic 
projections, and involve the transfer of substances 
between neurons, was by Saper et al. [165]. More 
recent research confirms these ideas and suggests 
that pathogenic proteins, including tau, a-synucle-
in, the disease form of prion protein (PrPsc), and Ab 
may be secreted from cells, enter other cells, and 
seed small intracellular aggregates within these 
cells [73,184] (Fig. 1). Hence, tau and Ab could exit 
Tau
Ab
Tau
Ab
TNT
Exo
Sec
EndoL
Fig. 1. Possible cell to cell transfer of pathogenic 
proteins and spread of the pathology along ana-
tomical pathways. Tau and b-amyloid (Ab) could 
exit cells via exocytosis (Exo) or secretion (Sec) 
and enter a new cell by endocytosis (Endo) or by 
interactions with membrane lipids (L). Transfer 
may also occur via tunnelling nanotubes (TNT) 
which connect various neurons. 
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cells via exocytosis or secretion and enter a new 
cell by endocytosis or by interactions with mem-
brane lipids. Transfer may also occur via tunnelling 
nanotubes (TNT) which connect various neurons 
[184]. For example, if tau spreads from cell to cell in 
the cortex, the resulting NFT may exhibit a spatial 
pattern which reflects this spread. Previous studies 
have suggested non-random distributions of NCI in 
the cerebral cortex of various disorders, the inclu-
sions often exhibiting a distinct clustering pattern 
consistent with their spread via the cortico-cortical 
pathways [25]. 
Theories based on environmental factors
Many environmental factors have been linked to 
AD, but most studies relate to three such variables, 
viz., exposure to aluminium (Al), effect of head trau-
ma, and the influence of diet and malnutrition.
Aluminium 
Much of the evidence that Al is a cause of AD is 
circumstantial and controversial [21]. Epidemiologi-
cal studies [77,120,133] have found little correlation 
between environmental Al and AD. In addition, out 
of 13 studies, in which gross brain tissue has been 
analysed for Al, 9/13 found enhanced levels in AD 
brain, while 4/13 found no significant differences 
compared with control brains [34]. The significance 
of enhanced Al levels in brain is also unclear since 
damaged brains may accumulate Al [21]. The pres-
ence of Al may also be linked to the formation of 
SP and NFT. Studies have either reported [61], or not 
reported [109], Al in association with the cores of 
classic Ab deposits, but it is not clear whether this 
type of SP is especially frequent in AD [18]. Al has 
also been detected in pyramidal neurons containing 
NFT [142,143]. It has been suggested that Al can bind 
to DNA and affect processing of cytoskeletal pro-
teins resulting in the formation of NFT. Nevertheless, 
there is little evidence that Al can bind significant-
ly to DNA [57,120]. In addition, patients with renal 
failure, exposed to high concentrations of Al, do not 
develop cellular NFT [142]. Furthermore, whether or 
not exposure of experimental animals [52] or cell 
cultures [171] to Al results in NFT formation has been 
controversial. Experimentally induced cytoskeletal 
change usually results in the formation of straight 
10 nm filaments, unlike the majority of NFT, which 
are composed of 20-24 nm twisted filaments [190], 
and which have a different molecular composition 
in AD [81]. Finally, neuropsychological conditions, 
which arise from acute exposure to Al, such as dia-
lysis dementia [7] or bladder irrigation [131], in which 
a 1% alum solution is used to treat haemorrhagic 
cystitis, probably have little significance apart from 
demonstrating that Al in acute doses can be neuro-
toxic. 
Head injury
Head trauma results in a primary injury which 
frequently spreads via inflammatory cytokines to 
initially unaffected regions, thus amplifying the orig-
inal injury due to the activation of microglia and 
central nervous system immune cells [71]. Several 
observations suggest a link between head injury 
and AD. In survivors of head injury, APP is observed 
in neuronal perikarya and in DN surrounding Ab 
deposits, as in AD [68]. The formation of Ab from 
APP occurs within the synaptic terminal fold of 
axons, the presence of glia not being necessary for 
this conversion. Hence, the production of APP may 
be a component of the brain’s response to neuronal 
injury [68]. Subsequently, it was shown that specific 
neurons in the medial temporal lobe secreted large 
quantities of APP and that there were more APP-im-
munoreactive neurons in these areas in head injury 
patients [124]. Hence, an increased expression of 
APP in head trauma cases may be an acute phase 
response to neuronal injury [161], the overexpres-
sion of APP leading to the deposition of Ab. Several 
acute phase proteins are localised within Ab depo-
sits in AD including amyloid-P, complement factors, 
and a-antichymotrypsin [98]. Furthermore, Regland 
and Gottfries [154] proposed that APP maintains cell 
function by supporting neuronal growth and survi-
val. The possible neurotrophic action of APP is sup-
ported by the observation that it shares structural 
features with the precursor for the epidermal growth 
factor [154]. NFT may also be a part of the neurons 
response to injury [205]. These studies suggest that 
the formation of pathological proteins as a result of 
brain injury is one method by which AD pathology 
develops and is then propagated within the brain by 
cell to cell transfer.
Diet and malnutrition
Abalan [1] was one of the first authors to pro-
pose that AD could be caused by malnutrition. This 
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hypothesis is based on clinical observation of AD 
patients who often exhibit emaciation and cachexia, 
urinary tract infections, terminal bronchopneumo-
nia, and low triceps skinfold. Low serum albumin, 
iron, folate, tryptophan, vitamin B12, and low cere-
bral metabolism of glucose and oxygen may also be 
present. These symptoms suggest a protein calorie 
malnutrition syndrome in AD which could result in 
the development of NFT due to chronic nutritional 
deficiencies of calcium and magnesium. A problem 
with this type of hypothesis, however, is in deter-
mining cause and effect, as malnutrition could be 
a consequence of the disease resulting from the 
mental state of the patient [1]. A more direct demon-
stration of a link between diet and AD has been 
reported by Sparks et al. [182] in which deposition 
of Ab was induced in rabbits fed with high levels of 
dietary cholesterol. In addition, McCaddon and Kelly 
[121] found in a human family carrying a mutation of 
the APP gene (APP717, Val-Glycine), that individuals 
with AD had a greater vitamin B12 deficiency, com-
pared with unaffected members. It was concluded 
that this link was unlikely to be secondary and to 
be a consequence of impaired dietary intake. A B12 de-
ficiency could then result in a reduction of mono-
amine transmitters and in cholinergic activity. 
Theories based on genetics
In the 1990s, strong evidence emerged of the 
connection between familial AD (FAD) and specific 
genetic factors. Hence, small numbers of cases were 
linked to APP mutations [48,74] and a larger sub-
group to PSEN1/2 mutations [112,173], while others 
genes are currently unidentified [179]. In addition, 
allelic variation in the Apo E locus on chromosome 19 
was identified as a significant risk factor, especially 
in late-onset AD [185].
APP
A variety of Ab peptides are formed as a result of 
secretase cleavage of APP [79]. The most common 
of these peptides is Ab42, found largely in discrete 
Ab deposits, whereas the more soluble Ab40 is also 
found in association with blood vessels [125] and 
may develop later in the disease [54]. In addition, 
mutations of APP within the Ab coding region may 
result in the deposition of Ab38 in vessel walls, espe-
cially in those cases with extensive cerebral amyloid 
angiopathy (CAA) [128]. Causation of AD could also 
be attributable to early soluble peptide oligomers 
[69], which vary with the type of mutant, thus pro-
viding a genetic basis for variations in pathogenesis 
among FAD cases. The discovery of Ab led to the for-
mulation of the ‘Amyloid Cascade Hypothesis’ (ACH), 
the most influential model of the molecular patho-
logy of AD developed over the last 25 years [84] 
(Fig. 2). Essentially, the ACH proposes that the depo-
sition of Ab peptides is the initial pathological event 
in AD leading to the formation of SP and NFT, and 
then to cell death and dementia, both SP and NFT 
acquiring several additional proteins during their 
formation, such as Apo E, ubiquitin, and comple-
ment [14]. 
Evidence in support of the ACH comes from seve-
ral sources. First, experiments using transgenic mice 
expressing high levels of APP result in Ab deposition, 
APPm, PSEN1/2m
Ab1-42
Senile plaques
Complement 
proteins
Apo E
Ub GFAP, AbTau + NFT
Cell deathApoptosis Necrosis
Perturbation of cellular  
homeostasis
Dementia
Fig. 2. The original Amyloid Cascade Hypothe-
sis (ACH). The ACH proposes that the deposition 
of b-amyloid (Ab) peptides is the initial patho-
logical event in AD leading to the formation of 
senile plaques (SP) and neurofibrillary tangles 
(NFT), and then to cell death and dementia, 
both SP and NFT acquiring several additional 
proteins during their formation, such as apoli-
poprotein E (Apo E), glial fibrillary acidic protein 
(GFAP), ubiquitin (Ub), and complement. Other 
abbreviations: Amyloid precursor protein muta-
tions (APPm), Presenilin genes 1 and 2 muta-
tions (PSEN1/2m).
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synaptic loss, and gliosis [66]. Second, FAD caused 
by APP717 (valine–isoleucine) mutation have signifi-
cant numbers of NFT thus supporting a link between 
APP and the cytoskeleton [110]. Third, cases linked 
to PSEN1 have greater numbers of SP and NFT com-
pared with cases of sporadic AD (SAD) suggesting 
that PSEN1 may also increase tau deposition [172]. 
There are two main problems regarding the ACH 
as originally formulated. First, as demonstrated in 
head injury patients, SP and NFT may be reactive 
products resulting from cellular neurodegeneration 
rather than being its cause [27]. The results of ani-
mal experiments also suggest that the formation of 
Ab could be a reactive process. Experimental lesions 
that damage the nucleus basalis in rat brain elevate 
APP synthesis in the cerebral cortex suggesting that 
the production of APP is a specific response to loss 
of functional innervation [199]. In addition, chemical 
lesions of the nucleus basalis using N-methyl-D-as-
partate (NMDA) elevate APP synthesis in cortical 
polysomes [199] and, in areas of brain damaged by 
kainite [101], APP695 was recorded in DN near to 
the lesion. Intrathecal or intraparenchymal injec-
tions of a toxin also induced APP in hippocampal 
neurons subsequent to neuronal damage [97]. 
Lesion experiments may also induce patholo-
gical changes leading to NFT. Denervation of the 
dopamine pathways and septal lesions which affect 
both the cholinergic system and g-aminobutyric acid 
(GABA) neurons projecting to the dentate gyrus, for 
example, result in loss of dendritic microtubule asso-
ciated protein 2 (MAP2) and tau-immunoreactivity in 
dentate gyrus granule cells [193]. Hence, denervation 
may cause transsynaptic changes in dentate gyrus 
neurons which represent a precursor stage to NFT.
The second objection to the ACH is that there is 
no generally accepted mechanism to explain how Ab 
deposition leads to NFT [59]. There have been sever-
al attempts to establish such a mechanism but none 
have become universally accepted. First, Ab may 
promote the formation of intracellular tau, although 
the mechanism of this interaction was uncertain 
[70]. Second, there may be a synergistic interaction 
between NFT and Ab [136,177]. Third, when foetal 
rat hippocampal and human cortical neurons were 
treated with Ab, fibrillar forms of Ab could apparent-
ly induce tau phosphorylation. Hence, amyloid fibril 
formation might alter the phosphorylation state 
of tau resulting in the loss of microtubule binding 
capacity. 
Studies have also suggested that SP and NFT 
occur in distinct but independently distributed pat-
terns in AD [19,93]. Studies of the spatial patterns of 
SP and NFT show them to be clustered, the clusters 
often being regularly distributed parallel to the pia 
mater [8]. Clusters of SP and NFT, however, are fre-
quently distributed independently of each other, i.e., 
neither in nor out of phase, which would not support 
a direct pathogenic link between them. In addition, 
SP and NFT may be separated in the brain both in 
space and in time [119]: in the entorhinal cortex, for 
example, NFT may precede the appearance of SP 
[59]. Perez et al. [140], however, showed that Ab25-35 
could result in tau aggregation and that a decrease 
in Ab aggregation was induced by tau peptides. 
Hence, aggregation of tau may be correlated with 
disassembly of Ab which could explain the lack of 
spatial correlation of the SP and NFT [19].
In transgenic experiments [13], the presence of 
APP mutations alone or in combination with PSEN1 
can induce Ab deposits in normal brain. Apart from 
evidence of hyperphosphorylated tau in DN asso-
ciated with the plaques, these mutations do not 
appear to induce tau pathology or a significant in-
flammatory response. Hence, the presence of tau 
transgenes in the form of a triple model appears to 
be necessary to completely replicate AD pathology 
[13]. Hence, the ACH as originally formulated does 
not appear to provide a complete explanation for AD.
PSEN genes
The most common type of FAD is linked to muta-
tions of the PSEN genes [112,173] and the effect of 
these mutations is also assumed, albeit more indi-
rectly, to lead to the enhanced deposition of Ab [79]. 
Full length PSEN is composed of nine trans-mem-
brane domains located on the endoplasmic reticu-
lum membrane. Endoproteolytic cleavage of PSEN 
and assembly into g-secretase complex is followed 
by transport to the cell surface, thus potential-
ly influencing APP processing [92]. Hence, mutant 
PSEN1 could enhance 42-specific-g-secretase cleav-
age of normal APP resulting in increased deposition 
of amyloid-forming species [188]. PSEN may also act 
through loss of function by a reduction in g-secre-
tase activity [206].
PSEN, however, may have a variety of other func-
tions. The PSEN1 gene may be involved in notch sig-
nalling [183] and therefore important in cell differen-
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tiation. PSEN1/2 genes may also be involved via the 
perturbation of cellular calcium homeostasis [207] 
or in interactions with the transcriptional coactiva-
tor cAMP-response element binding (CREB-binding) 
protein which plays a key role in regulating gene 
expression [64]. PSEN1 may also mediate neuropro-
tective functions by ephrin-B [32] and a decline in 
such protection could be involved in AD.
Apo E
An allelic variation in Apo E has been identified 
as a major risk factor in late-onset AD, individuals 
with AD having 2-3 times the frequency of allele e4 
compared with cognitively normal individuals [185]. 
In addition, allele e4 may accelerate the develop-
ment of AD pathology within the aging brain [137] 
and hence, is often associated with an earlier dis-
ease onset [75]. 
The relationship between the deposition of Ab 
and Apo E genotype has been controversial. The ma-
jority of studies, however, report increased amy-
loid deposition in individuals expressing allele e4 
[35,38,152]. In addition, the clustering pattern of NP 
may reflect the degeneration of specific cortico-cor-
tical and cortico-hippocampal pathways [10]. Cellu-
lar NFT often occur in regularly distributed clusters 
along the cortex [8] and NP may develop on the 
dendrites and axon terminals of NFT containing cells 
[53,139]. Individuals expressing allele e4 are asso-
ciated with the development of NP in smaller and 
denser clusters compared with the other Apo E ge no-
types, which may reflect a more specific pattern of 
neurodegeneration [22].
Other genes
APP and PSEN1/2 genes together account for 
less than 5% of cases of AD [78,90]. Late-onset AD 
(LO-AD) is likely to be a multifactorial disease with 
the potential involvement of multiple genes. Hence, 
genome wide studies have revealed genes on chro-
mosomes 6, 9, 10, 11, 12, 14, 18, 19, and the X chro-
mosome could be involved in AD [44,176] with the 
most compelling case for a gene on chromosome 12 
[138]. Further studies map this locus to 12q13, a re-
gion which encompasses the vitamin D receptor 
(VDR) gene [200]. This gene is a major mediator of 
the activity of vitamin D and insufficiency of this 
vitamin has been implicated as a risk factor for AD. 
In addition, the glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) gene has been implicated in 
LO-AD [3]. A major problem with postulating genetic 
factors as the cause of AD, however, is the similarity 
of FAD and SAD phenotypes [49,134] and therefore, 
no specific gene mutation is an essential condition 
to generate the AD phenotype.
Theories based on mitochondrial 
dysfunction
Theories that AD may be due to mitochondrial 
dysfunction have a long history [39] and rely on sev-
eral lines of evidence. First, an early change in AD is 
the presence of swollen and distorted mitochondria 
accompanied by a decline in the cerebral metabolic 
rate [39]. Second, there may be a deficiency of sev-
eral enzymes involved in carbohydrate utilization in 
AD including such mitochondrial markers as phos-
phofructokinase (PFK) and pyruvate dehydrogenase 
[39]. Third, part of the familial aggregation of AD 
may be accounted for by excess maternal versus 
paternal inheritance, consistent with mitochondrial 
inheritance. Hence, genomic analysis of 1007 indi-
viduals suggested that possession of specific hap-
lotypes could reduce the risk of AD, and therefore, 
there is a possibility of haplotypes that would 
increase the risk [159]. The possibility of a genetic 
origin of mitochondrial dysfunction in AD has led 
to the formulation of the ‘mitochondrial cascade 
hypothesis’ (MCH) in which it is the mitochondri-
al dysfunction that is the root cause of the events 
leading to the ACH [189]. Nevertheless, it is possible 
that mitochondrial dysfunction is a further conse-
quence of the ACH [189]. Fourth, ‘adaptor protein 
evolutionarily conserved signalling intermediate in 
Toll pathway’ (ECSIT) is a protein which may act as 
a molecular sensor, ascertaining cell homeostasis in 
response to oxidative damage by Ab [178]. Protec-
tive molecules could then be specifically activated in 
response and this failure could result in severe mito-
chondrial damage, promote apoptosis, and result in 
synaptic dysfunction and neuronal death [178]. 
Theories based on blood brain barrier 
dysfunction 
The involvement of the cerebral blood vessels 
in the pathogenesis of AD has been controversial 
[30]. Some studies have found spatial correlations 
between Ab deposits and blood vessels suggesting 
that degeneration of blood vessels or diffusion of 
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substances from vessels could be involved in the 
formation of Ab deposits [127,145,146]. By contrast, 
other studies conclude that the spatial correlations 
observed between Ab deposits and blood vessels are 
fortuitous and arise because of the presence of high 
densities of capillary profiles and Ab [102,115]. In 
the cerebral cortex of cases of SAD, however, of the 
three Ab deposit subtypes, only the classic Ab depos-
its exhibited a consistent spatial relationship with 
blood vessels [15,23]. Classic deposits were clustered 
specifically around larger blood vessel profiles, such 
as the vertically penetrating arterioles, the number 
of classic deposits declining exponentially with dis-
tance from the vessels [15]. 
A number of factors could explain the correlation 
between Ab deposits and blood vessels in AD (Fig. 3). 
First, Ab could develop in association with the base-
ment membranes or smooth muscle of blood ves-
sel walls [145,204]. Tian et al. [192] found that blood 
vessels underwent degenerative changes in AD 
accompanied by Ab deposition and loss of smooth 
muscle cells. Second, Ab could be released by axon 
terminals or reactive glial cells juxtaposed to vessel 
walls [96]. Attems et al. [30], for example, found that 
Ab42 was deposited within the glia limitans rather 
than the capillary walls. Third, diffusion could occur 
from degenerating arterioles or from clusters of cap-
illaries surrounding the larger blood vessels. Blood 
vessels with collapsed or degenerated endothelia 
are evident in more than 90% of AD cases [100] and 
occur concurrently with Ab deposition. The integri-
ty of the brain microvasculature may be related to 
neuronal degeneration and especially to age-related 
cell losses in the LC [87,116]. In AD transgenic mice, 
deposition of Ab in blood vessels is associated with 
endothelial cell activation and apoptosis [170], which 
could encourage diffusion. Endothelial cell injury 
could also depend on duration of dementia [192]. 
If diffusion is involved in the pathogenesis of the 
classic Ab deposits, then various plasma proteins 
may be implicated. Amyloid fibrils have been ob serv-
ed projecting directly from blood vessels towards 
classic-type deposits [196] suggesting that Ab itself 
could diffuse from blood vessels. How ever, most Ab 
deposited in the cortex is likely to be of neuronal ori-
gin [4,12]. A number of other plasma proteins could 
be involved including amyloid-P, a-antichymotryp-
sin, antitrypsin, antithrombin III as well as comple-
ment factors [96,97] and Apo E [165]. The mRNAs 
of these proteins, however, is found in brain tissue 
suggesting that they are made in situ [97]. The likely 
exception is amyloid-P since the liver is the only tis-
sue of the body which exhibits its mRNA [97]. Plas-
ma proteins, such as amyloid-P, may act as ‘molec-
ular chaperones’ and be involved in the aggregation 
of Ab to form plaque amyloid. Hence, secondary 
damage to cerebral vessels as a result of Ab depo-
sition from neurons could result in the leakage of 
plasma proteins from the larger diameter blood ves-
sels. These proteins could then enhance the conden-
sation of already formed Ab to form a solid amyloid 
core resulting in the observed pattern of dispersion 
of classic deposits around blood vessels.
Fifth, deposition of Ab around the larger blood 
vessels could be a result of impaired drainage. Extra-
cellular fluid is drained from the brain to the cervical 
lymph nodes via the perivascular channels [191] and 
therefore, Ab around vessels could be attributable to 
overloading of this system. Such a process could also 
lead to enhanced deposition of Ab in the immediate 
vicinity of the blood vessel and a negative exponen-
tial distribution of amyloid deposits. Sixth, another 
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Fig. 3. Relationships between the cerebral micro-
vasculature and the development of cored (clas-
sical) senile plaques (SP). b-amyloid (Ab) could 
develop in association with the basement mem-
branes or smooth muscle (S) of blood vessel 
walls or Ab could be released by axon terminals 
or reactive glial cells juxtaposed to vessel walls. 
Diffusion of proteins such as amyloid-P could 
also occur from degenerating arterioles or from 
clusters of capillaries surrounding the larger 
blood vessels and influence cored SP develop-
ment. Deposition of Ab around the larger blood  
vessels could also be a result of impaired drain-
age. Other abbreviations: Capillary end feet (CEF), 
Neuron (N). 
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function of Ab may be to serve as an acute response 
to vessel damage and to seal vascular leakage [106].
Vascular pathology may also be involved in the 
pathogenesis of Ab deposits in FAD. Hence, plasma 
Ab may be increased in FAD as well as in SAD [187]. 
In addition, a proportion of FAD cases exhibit CAA 
similar to that observed in SAD, viz., the deposi-
tion of Ab in and around the major blood vessels. 
Mutations of the APP gene within the Ab region are 
often associated with familial CAA [174] while APP 
mutations outside the Ab region result in a pathol-
ogy deficient in Ab40, and with lower levels of CAA 
[108]. In addition, possession of one or more ApoE 
e4 alleles significantly increases the risk of AD, and 
could also be linked to vascular pathology. In trans-
genic mice, for example, ApoE markedly promotes 
CAA associated vessel damage [65].
Theories based on immunology
There are several lines of evidence supporting 
the presence of immune system dysfunction in AD 
[123,132,162]. Complement proteins associated with 
the ‘classical’ pathway [123], brain reactive antibo-
dies [132], immunoglobulins [62,95], circulating im-
mune complexes (CIC) in peripheral tissue and cere-
bral blood vessels [86], helper/inducer and cytotoxic/
suppressor T-cells [123], and abundant reactive micro-
glia [123] have all been observed in AD. Complement 
system proteins may act as pattern recognition mole-
cules mediating the uptake of Ab by glial cells which 
express complement receptors [195]. Significant alter-
ations in the major histocompatibility locus (MHC) 
antigens have also been demonstrated [197] suggest-
ing either increased resistance or susceptibility to an 
antigen in AD [50,88]. These immune reactions could 
be a response to the pathological processes of AD and 
especially to the deposition of Ab. However, of more 
interest is whether immune reactions to an environ-
mental antigen could be a cause of AD.
Studies suggest that exposure to metals can in -
duce an immune response in peripheral tissues [20]. 
First, mercury can induce antibodies against renal 
antigens and inhibit RT6+ T-cells [107]. Second, expo-
sure to cobalt, Al [21], tin, zirconium, and beryllium 
have been associated with lung inflammatory dis-
ease [63]. Lymphocyte transformation, an increase 
in T-cells, and the development of a granulomatous 
pneumonitis have been observed in these disor-
ders [63]. Third, Al phosphate and hydroxide are 
used as vaccine adjuvants [83], i.e., they enhance 
the immune response to an antigen [60]. Adjuvants 
containing Al can activate complement proteins 
[153], prime helper T-cells for IgE production [104] 
and induce antibody [155]. Since many metals can 
be absorbed into the brain [34], it is possible that 
a metal-induced immune activation could occur in 
brain and contribute to the pathogenesis of AD.
The essential features of a possible hypothesis 
have been proposed by Sartvetnick and Fox [166] 
(Fig. 4). The immune system can respond to antigens 
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Fig. 4. Hypothesis to explain how an immune reac-
tion to metal ions could cause AD. Metals such as 
Aluminium (Al) entering cells via transferrin recep-
tors (Al-Tf) could result in the production of CD4+ 
T-cells which recognise peptide fragments (Pe) 
taken up by macrophages and other cells result-
ing in an immune response. CD4+ T-cells may infil-
trate the neuropil and cluster around antigen-pre-
senting cells. T-cells release lymphokines, such as 
interferon-gamma (ITN-g), which activate micro-
glia (Ac-Mg) resulting in the formation of free rad-
icals and an oxidative attack which can damage 
adjacent neurons. These processes could result 
in an increase in amyloid precursor protein and 
PHF-tau, the formation of b-amyloid (Ab), and 
ultimately senile plaques (SP), and neurofibrilla-
ry tangles due to loss of synaptic connections.  
Other abbreviations: Capillary endothelial cells 
(CEC), Major histocompatibility locus (MHC), Pair-
ed helical filament (PHF). 
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expressed by the major histocompatibility complex 
(MHC) pathway expressed in non-immune cells, 
MHC-antigen complexes on the cell surface then 
initiating a T-cell response. Hence, metals entering 
cells via transferrin receptors or directly could bind 
to peptide fragments and result in the production of 
CD4+ cells [122] which recognise peptide fragments 
taken up by macrophages and other cells. Potential-
ly pathogenic metals such as Al could therefore be 
taken up into antigen-presenting cells in the brain 
resulting in an immune response. This is unlikely to 
occur in neurons or in astrocytes directly, as they 
do not express MHC antigens [123], but could occur 
in microglia or capillary endothelial cells which do 
express these antigens. The result could be the pro-
duction of CD4+ T-cells which infiltrate the neuropil 
as a consequence of disruption of the blood brain 
barrier, and cluster around antigen-presenting cells. 
T-cells release lymphokines, such as interferon-gam-
ma (ITN-g), which activate microglia [201] resulting 
in the formation of free radicals and an oxidative 
attack, which can damage adjacent neurons. In 
addition, the pro-inflammatory cytokine IL-15 is pro-
duced by activated blood monocytes, macrophages, 
dendritic cells, and activated glia, and can cause 
T-cell proliferation and induction of cytolytic effector 
cells resulting in the formation of immunoglobulins 
[157]. These processes could result in an increase in 
APP and PHF-tau and the formation of Ab, SP, and 
NFT due to loss of synaptic connections. Neverthe-
less, even if a metal such as Al enters neurons, there 
is little evidence that it reacts with MHC proteins in 
human brain cells and no evidence linking variations 
in MHC antigens in AD and susceptibility to met-
al-induced immunity. Moreover, there is also doubt 
as to the degree to which effector CD4+ T-cells can 
enter the neuropil. In addition, there is no evidence 
that such a process results in Ab deposits, SP, or 
NFT. The most obvious immune response observed 
in histological preparations of AD brain is the pres-
ence of microglia associated with mature Ab depos-
its [119,135], which supports the hypothesis that the 
immune reactions are likely to occur as a response to 
the production of Ab.
A further immunological factor in AD involves 
the action of peptidyl-arginine deiminases (PAD), 
enzymes which catalyse a post-translational reac-
tion termed ‘citrullination’ by converting arginine 
to citrulline [2]. A selective expression of PAD2 and 
PAD4 in astrocytes and neurons respectively results 
in a citrullinated protein expression in the hippo-
campus and cerebral cortex. Hence, neuronal loss 
in AD could result from the loss of cellular con-
tents, including citrullinated proteins, resulting in 
an auto-immune response and the production of 
auto-antibodies [2].
Theories based on infectious agents
Indirect evidence that infection could be a cause 
of AD has been reported by Wisniewski et al. [203] 
who suggested that invasion by a virus could cause 
activation of microglia and pericytes and ultimate-
ly, amyloid deposition. In addition, Libikova et al. 
[113] suggested that the virus herpes simplex (HSV), 
to which antibodies may be observed in the cere-
bral spinal fluid (CSF) in AD, could induce abnormal 
protein formation and result in PHF and NFT. This 
type of theory has been given further credibility by 
observations of marked structural and biochemi-
cal alterations in regions associated with olfaction, 
most notably the olfactory bulb and EC [58]. The ol-
factory system is a possible point of entry into the 
brain for an infectious agent or protein [117]. Hence, 
experimentally introduced viruses into body cavities 
and organs often result in high titres of the virus in 
olfactory epithelium, olfactory bulb, and other brain 
regions. Nevertheless, it is unlikely that HSV is the 
responsible virus, as it does not typically enter the 
brain via the olfactory system [164].
Recent research on cell to cell transfer of patho-
genic proteins has re-established interest in infec-
tious agents as a cause of AD and related neurode-
generative diseases [73,184]. The similarity in the 
properties of Ab and PrPsc in AD and Creutzfeldt-Ja-
kob disease (CJD), respectively [26], has also con-
tributed to this debate. Such cell to cell transfer 
raises the possibility, first proposed by Braak and 
colleagues [85], that in PD, a pathogenic agent intro-
duced via ingestion and/or inhalation, may transfer 
along axons to basal areas of brain, the brain stem, 
and then to the cerebral cortex. Hence, in PD, a-sy-
nuclein could be the target of the unknown agent 
causing protein misfolding and subsequent spread 
via connecting cells (Fig. 1). a-Synuclein taken up 
from the extracellular space can induce aggregation 
of other a-synuclein proteins in recipient cells. By 
analogy with PrPsc, nucleation or seeding activity of 
a-synuclein may result in a core of transferred a-sy-
nuclein surrounded by additional layers of cytoplas-
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mic a-synuclein contributed by the host cell. Ab and 
tau may also have these properties and therefore, 
cell to cell transfer of an externally acquired infec-
tious agent or protein could be involved in AD.
Discussion
Consideration of the theories
Many theories have been advanced as to the 
cause of AD and the objective of this section is to 
select those, which on the basis of the evidence, 
are most likely to be involved and then to assemble 
them into a plausible theory. Any theory of AD would 
need to explain a number of key observations: (1) the 
heterogeneity characteristic of AD, (2) the overlap 
between AD and aging, (3) the similarity of FAD and 
SAD, (4) that Ab and tau may be reactive proteins, 
(5) that some cases of AD have few SP and/or NFT, 
(6) that the pathology is spatially related to cerebral 
blood vessels, and (7) the immunological responses.
One of the major problems in assessing the valid-
ity of any theory is that it is not clear whether it is 
a primary or secondary event. The theories which 
have had the most longevity and impact are the cho-
linergic hypothesis and the ACH. Both are involved in 
the pathogenesis of AD, but do not provide a com-
plete theory. Hence, there is evidence of cholinergic 
dysfunction in AD, but only as part of a multi-system 
degeneration. In addition, the ACH has two prob-
lems, viz., SP and NFT may be reactive rather than 
causal [27], and there is no accepted mechanism to 
explain how Ab leads to NFT. Hence, the cholinergic 
hypothesis is unlikely to be the primary cause of AD 
and the ACH in its present form requires modifica-
tion to be included in a general theory. 
Of the remaining theories, interest in Al and oth-
er metals as a cause of AD has declined, although 
there is some evidence that Al could accumulate in 
the brain, interact with processes that result in Ab 
deposition and tau formation [20], and that metals 
may cause an immune reaction in brain. In addition, 
hypotheses derived from the study of malnutrition 
and head injury, suggest that these are likely to 
be risk factors for AD rather than primary causes. 
Immunological changes and mitochondrial dysfunc-
tion in AD are also likely to be reactions to earlier 
pathological processes such as the formation of 
abnormal proteins. 
By contrast, there is a clear connection between 
AD and normal aging [158], all features of AD can 
be observed to some degree in a cognitively normal 
brain. An important aspect of aging is age-related 
decline in LC neurons, and its effects on the blood 
brain barrier could play a role in the disease [87,116]. 
In addition, there is strong evidence that degenera-
tion of specific anatomical pathways and the spread 
of the pathology by cell to cell transfer is important 
in AD.
A possible theory 
It is hypothesised first, that the primary factor in 
AD is an age-dependent breakdown of anatomical 
systems and pathways within the brain and the con-
sequence loss of synapses [47] (Fig. 5). The extent of 
this aging effect, which begins early in life, is medi-
ated by the degree of lifetime stress (the ‘allostatic 
load’). The brain is the ultimate mediator of stress- 
related mortality through hormonal changes result-
ing in hypertension, glucose intolerance, cardiovas-
cular disease, and immunological problems [47]. 
The consequence is gradual synaptic disconnection, 
neuronal degeneration, and the upregulation of ge- 
nes determining various reactive and breakdown 
products such as Ab and tau [27,149,154,199]. These 
changes are most manifest initially in the EC which 
has a high proportion of APP reactive cells. In addi-
tion, cell losses in the LC may begin to affect the 
integrity of the blood brain barrier resulting in the 
release of proteins with chaperone-type activity. 
Second, in small numbers of families, specific APP 
or PSEN mutations directly influence the outcome of 
this age-related degeneration by determining the sol-
ubility and/or toxicity of the molecular product. Cells 
have mechanisms to protect against the accumula-
tion of misfolded and aggregated proteins including 
the ubiquitin system and the phagosome-lysosome 
system. Neuronal degeneration in individuals with 
specific mutations results in the rapid formation of 
pathogenic Ab and tau, and then phases of ‘second-
ary’ neurodegeneration, which overwhelms the pro-
tection systems. Early onset FAD is the consequence 
of this process. Once initiated, Ab and tau are then 
likely to be propagated through the brain via cell to 
cell transfer from their origin in the medial temporal 
lobe to the hippocampus and cerebral cortex.
By contrast, in individuals without a specific 
ge netic mutation, but where more complex genetic, 
e.g. Apo E, and environmental risk factors are pres-
ent, the outcome of age-related loss of synapses is 
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mainly soluble and smaller quantities of insoluble 
proteins which are degraded by the cellular protec-
tion systems and do not significantly accumulate 
to form SP and NFT. With advancing age, however, 
the protec tive systems become ess effective result-
ing inslowly accumulating quantities of Ab and tau. 
The re sult of these insidious processes is that the cel-
lular protection systems do not become overwhelmed 
until much later in life, the consequence being late 
onset SAD. Subsequently, there are a number of res-
ponses to neurodegeneration including a further 
dis ruption of the blood brain barrier, an immunolo-
gical response, and mitochondrial dysfunction which 
could initiate phases of secondary degeneration. Dis-
ease heterogeneity [24] is attributable to variations 
in the pathways of spread of the pathology from its 
origin in the medial temporal lobe. 
Predictions of the theory
The theory suggests that it is aging and the dis-
eases associated with aging that provide the trig-
ger initiating the cascade of events leading to AD, 
rather than the initial deposition of Ab, and makes 
a number of predictions. First, the hypothesis pre-
dicts that significant signs of neuronal degeneration 
in AD should precede those of Ab deposition and 
that the effect of Ab is secondary rather than prima-
ry in causing neurodegeneration. Second, that the 
pathogeneses of SP and NFT are not directly linked 
and the two lesions essentially arise independently. 
Third, in transgenic experiments, the effect of the 
transgene will be age-dependent. In a model which 
incorporates an APP: V717I mutation, for example, 
there was an age-related loss of pyramidal neurons 
in the hippocampus CA sectors including at sites 
devoid of plaque deposition [169] consistent with 
this prediction. 
Implications
First, the theory suggests that AD is not a dis-
ease linked primarily to defective genes but a com-
plex syndrome dependant on the rate of aging and 
indirectly influenced by genetic risk factors and 
the environment. Second, the hypothesis questions 
whet her the presence, distribution, and molecular 
determinants of SP and/or NFT should continue to 
play an important role in pathological diagnosis. 
Hence, if SP/NFT are the products of brain degener-
ation and not its cause, they will represent relatively 
late stages in pathogenesis and there may be cases 
of AD that are difficult to classify because they may 
have insufficient numbers of SP and NFT or exhibit 
early developmental stages of these pathologies. In 
addition, if SP and NFT represent the consequenc-
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Fig. 5. A possible theory of Alzheimer’s disease (AD). External and internal factors act together to increase 
the rate of normal aging (‘allostatic load’), leading to degeneration of neural pathways and blood vessels 
and resulting in the formation of b-amyloid (Ab) and tau and then senile plaques (SP) and neurofibrillary 
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es of specific types of neurodegeneration [11] rath-
er than being characteristic of AD, then many cases 
may show combinations of pathological features, 
i.e., there will be a considerable degree of overlap 
between different disorders. Numerous examples of 
such cases have been reported in the literature, e.g., 
dementia with Lewy bodies (DLB) with associated 
AD pathology, Creutzfeldt-Jakob disease (CJD) with 
AD, Pick’s disease (PkD) with AD, and these cases 
are often difficult to classify [17,28]. Third, should 
significant effort continue to be devoted to immuno-
therapy and other treatments designed to remove 
Ab from the brain? Such treatments could limit the 
degree of secondary degeneration induced by Ab. 
Nevertheless, Ab might be beneficial to the nervous 
system by promoting neurogenesis [114] and having 
a range of other protective functions [111]. In addi-
tion, excessive removal of Ab could reduce chelation 
within the brain and result in enhanced oxidative 
stress [31].
Conclusions
Many theories have been advanced as to the 
cause of AD including those based on: (1) aging, 
(2) degeneration of anatomical pathways, (3) environ-
mental factors, (4) genetic factors, (5) mitochondrial 
dysfunction, (6) vascular factors, (7) immune system 
dysfunction, and (8) infectious agents. It is proposed 
that AD is a multifactorial disorder in which external 
and internal factors act together to increase the rate 
of normal aging (‘allostatic load’). The consequent 
degeneration of neural pathways and blood vessels 
results in the formation of abnormally aggregat-
ed proteins such as b-amyloid and tau which then 
spread, via cell to cell transfer, from the medial tem-
poral lobe to affect association areas of brain and 
then the primary sensory areas. Variation in the path-
ways of spread leads to the disease heterogeneity 
characteristic of AD.
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